Peptide research library

A stable peptide derived from a protective protein found in human gastric juice. In preclinical research it is studied for tissue repair and angiogenesis, acting through pathways including VEGFR2 activation and nitric-oxide-system modulation, with documented interest in tendon, ligament, muscle and gastrointestinal healing models.

Regulatory & legal statusNot FDA-approved. Placed on the FDA Category 2 bulk drug substances list (2023). Banned by WADA (S0, since 2022).

Represents the active region (LKKTETQ motif) of Thymosin Beta-4, a naturally occurring protein involved in cell migration and angiogenesis. Researched for wound-healing and tissue-repair models via actin sequestration. Note that Thymosin Beta-4 is upregulated in some metastatic cancers, a theoretical concern flagged in the literature.

Regulatory & legal statusNot FDA-approved for human use. Banned by WADA and in competitive horse racing.

A growth-hormone-releasing-hormone analog studied for its effect on pituitary GH and IGF-1 levels. Exists in a short-acting form (no DAC) and a long-acting Drug Affinity Complex (DAC) form with very different half-lives; the two are pharmacologically distinct.

Regulatory & legal statusNot FDA-approved. Prohibited by WADA (S2, peptide hormones / growth factors).

A ghrelin-mimetic that binds the GHS-R1a receptor and is studied for selective GH release without the cortisol or prolactin elevation seen with older secretagogues. Frequently discussed alongside CJC-1295 in the research literature.

Regulatory & legal statusNot FDA-approved. Prohibited by WADA (S2).

A cyclic peptide derived from Melanotan II that acts centrally on melanocortin receptors. Unusually for compounds in this space, it received FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder — meaning the approved product is a prescription medication.

Regulatory & legal statusFDA-approved (Vyleesi, 2019) as a PRESCRIPTION drug. Contraindicated with PDE5 inhibitors; caution in uncontrolled hypertension.

A combination formulation of GHK-Cu, KPV, BPC-157 and TB-500 studied as a single research preparation targeting complementary tissue-repair, anti-inflammatory and extracellular-matrix-remodeling pathways. Has not been studied as a unit in formal human clinical trials.

Regulatory & legal statusResearch formulation. Components are not FDA-approved; BPC-157 and TB-500 are WADA-banned.

An investigational once-weekly agent that activates GLP-1, GIP and glucagon receptors, studied in obesity and metabolic trials with notable Phase 2/3 weight-loss results. It is not commercially available.

Regulatory & legal statusINVESTIGATIONAL — available only through clinical trials; not approved and not legally sold. Prohibited by WADA. Products marketed online are unregulated and potentially counterfeit.

A naturally occurring tripeptide (L-cysteine, L-glutamic acid, glycine) central to cellular antioxidant defense and Phase II liver detoxification. Studied for oxidative-stress and skin-related endpoints.

Regulatory & legal statusHolds GRAS (food) status. Injectable glutathione is not FDA-approved for any therapeutic indication; the FDA has warned about compounding it from dietary-grade powder.

A coenzyme essential to cellular energy production and a cofactor for sirtuins, PARP enzymes and CD38. Endogenous levels decline with age. Studied for metabolic, mitochondrial and neuroprotective endpoints, largely via oral precursor (NMN/NR) research.

Regulatory & legal statusNot FDA-approved as an injectable therapeutic. Most clinical evidence comes from oral precursor studies rather than injection.

One of the few known mitochondrial-derived peptides, acting through AMPK-dependent pathways and studied for metabolic-homeostasis and exercise-adaptation endpoints. Endogenous levels rise with exercise and decline with age.

Regulatory & legal statusNot FDA-approved; no completed human therapeutic trials. Flagged by USADA as a substance of interest for athletes.

A synthetic fragment of adrenocorticotropic hormone developed in Russia and studied for cognitive and neuroprotective endpoints, largely via increases in BDNF and modulation of monoamine neurotransmission.

Regulatory & legal statusA registered pharmaceutical in Russia; NOT FDA-approved in the U.S. Not currently on the WADA Prohibited List (2025), but status can change.

A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic and mild nootropic endpoints via GABAergic and serotonergic modulation, without the sedation associated with benzodiazepines.

Regulatory & legal statusA registered pharmaceutical in Russia; NOT FDA-approved in the U.S. Not currently on the WADA Prohibited List (2025).

A dual incretin receptor agonist with extensive Phase 3 human data across the SURMOUNT and SURPASS programs, studied for type 2 diabetes, chronic weight management and obstructive sleep apnea.

Regulatory & legal statusFDA-approved as a PRESCRIPTION drug (Mounjaro, Zepbound). Carries a boxed warning for thyroid C-cell tumors; multiple contraindications. Requires a licensed prescriber.

An aromatic-cationic peptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, studied for mitochondrial-function endpoints in aging, heart-failure and myopathy models.

Regulatory & legal statusFDA-approved (September 2025) ONLY for Barth syndrome, as a prescription drug. All other uses are investigational.

An ultrashort synthetic tripeptide from the Khavinson bioregulator program, studied for neuroprotective and circadian endpoints via gene-expression modulation. Most published human data uses oral administration.

Regulatory & legal statusNot FDA-approved. Research originates largely from Russian institutions with limited Western replication.

A synthetic tetrapeptide based on the pineal extract Epithalamin, studied over 25+ years as a geroprotective agent, with research interest in telomerase activation and melatonin regulation.

Regulatory & legal statusNot FDA-approved. The FDA has flagged potential immunogenicity concerns. Research originates largely from the Khavinson group in Russia.

A small molecule (not a peptide) that inhibits nicotinamide N-methyltransferase, an enzyme overexpressed in adipose tissue, studied for metabolic and body-composition endpoints in preclinical models.

Regulatory & legal statusNot FDA-approved; has not entered human clinical trials. Available for research use only.

A naturally occurring copper peptide found in human plasma, extensively studied for gene-expression modulation, collagen synthesis and wound-healing endpoints. Widely used topically in cosmetics.

Regulatory & legal statusUsed topically in cosmetic products. Injectable GHK-Cu is not FDA-approved. Contraindicated in Wilson's disease and copper-metabolism disorders.

A thymic peptide studied for decades in immune-modulation contexts, including hepatitis, immunosenescence and vaccine-response research. The synthetic analog thymalfasin is marketed in a number of countries.

Regulatory & legal statusApproved and marketed in several countries as Zadaxin; NOT FDA-approved in the U.S. Contraindicated in deliberately immunosuppressed individuals (e.g. transplant recipients).

A synthetic melanocortin-receptor agonist studied for pigmentation and libido endpoints. Its safety profile is a notable concern: the published literature documents systemic toxicity, including a case of rhabdomyolysis.

Regulatory & legal statusNot FDA-approved. Documented reports of serious adverse effects including rhabdomyolysis; sold illegally in many jurisdictions.